Drugs.com - Clinical Trials

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO)...

Apr 26, 2025 - 14:23
 0
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO)...
Read More

Tags:

Previous Article

AI Screening for Opioid Use Disorder Associated with Fewer Hospital Readmissions

Next Article

Combination Immunotherapy Shrank a Variety of Metastatic Gastrointestinal Cancers

Related Posts

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension

Mineralys Therapeutics Announces Late-Breaking Data fro...

Apr 26, 2025  0

Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia

Cellenkos Announces US FDA Orphan Drug Designation Gran...

Apr 26, 2025  0

Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

Chlamydia Vaccine Candidate Granted Fast Track Designat...

Apr 26, 2025  0